TY  - JOUR
AU  - Menden, Michael P
AU  - Wang, Dennis
AU  - Mason, Mike J
AU  - Szalai, Bence
AU  - Bulusu, Krishna C
AU  - Guan, Yuanfang
AU  - Yu, Thomas
AU  - Kang, Jaewoo
AU  - Jeon, Minji
AU  - Wolfinger, Russ
AU  - Nguyen, Tin
AU  - Zaslavskiy, Mikhail
AU  - AstraZeneca-Sanger Drug Combination DREAM Consortium
AU  - Jang, In Sock
AU  - Ghazoui, Zara
AU  - Ahsen, Mehmet Eren
AU  - Vogel, Robert
AU  - Neto, Elias Chaibub
AU  - Norman, Thea
AU  - Tang, Eric K Y
AU  - Garnett, Mathew J
AU  - Veroli, Giovanni Y Di
AU  - Fawell, Stephen
AU  - Stolovitzky, Gustavo
AU  - Guinney, Justin
AU  - Dry, Jonathan R
AU  - Saez-Rodriguez, Julio
PY  - 2019
DO  - 10.1038/s41467-019-09799-2
UR  - https://hdl.handle.net/10668/25009
T2  - Nature communications
AB  - The effectiveness of most cancer targeted therapies is short-lived. Tumors often develop resistance that might be overcome with drug combinations. However, the number of possible combinations is vast, necessitating data-driven approaches to find...
LA  - en
KW  - ADAM17 Protein
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Benchmarking
KW  - Biomarkers, Tumor
KW  - Cell Line, Tumor
KW  - Computational Biology
KW  - Datasets as Topic
KW  - Drug Antagonism
KW  - Drug Resistance, Neoplasm
KW  - Drug Synergism
KW  - Genomics
KW  - Humans
KW  - Molecular Targeted Therapy
KW  - Mutation
KW  - Neoplasms
KW  - Pharmacogenetics
KW  - Phosphatidylinositol 3-Kinases
KW  - Phosphoinositide-3 Kinase Inhibitors
KW  - Treatment Outcome
TI  - Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen.
TY  - research article
VL  - 10
ER  -